penicillanic acid has been researched along with ertapenem in 51 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 30 (58.82) | 29.6817 |
| 2010's | 21 (41.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ceesay, TP; Gesser, R; Graham, DR; Holtom, P; Lucasti, C; Malafaia, O; McAdams, A; Nichols, RL; Perez, NQ; Woods, GL | 1 |
| Citron, DM; Gesser, RM; Goldstein, EJ; Merriam, CV; Tyrrell, KL; Warren, Y | 1 |
| Friedland, I; Majumdar, A; Mixson, LA; Motyl, M; Woods, GL | 1 |
| Carides, A; Choe, KA; Christou, NV; Dellinger, EP; Fernandez, A; Malafaia, O; Rotstein, OD; Satishchandran, V; Solomkin, JS; Tellado, JM; Teppler, H; Yellin, AE | 1 |
| Gesser, R; McCarroll, K; Tellado, J; Teppler, H; Woods, GL | 1 |
| Gesser, RM; McCarroll, K; Teppler, H; Woods, GL | 2 |
| Zaĭtsev, AA | 1 |
| Adeyi, B; Angel-Muller, E; Hague, C; Higareda, I; Ismail, M; Roy, S; Teppler, H; Woods, GL | 1 |
| Gesser, RM; McCarroll, KA; Woods, GL | 2 |
| Meibohm, AR; Teppler, H; Woods, GL | 1 |
| Bethel, CR; Bonomo, RA; Helfand, MS; Hujer, AM | 1 |
| Gesser, RM; Graham, DR; Meibohm, AR; Roy, S; Solomkin, J; Teppler, H; Woods, GL | 1 |
| Friedland, IR; Gesser, RM; Herman, G; Isaacs, R; Meibohm, A; Mistry, G; Teppler, H; Woods, GL | 1 |
| Baysallar, M; Doğanci, L; Kiliç, A; Küçükkaraaslan, A; Senses, Z | 1 |
| Chan, CY; Dinubile, MJ; Friedland, I; Giezek, H; Motyl, MR; Quinn, JP; Shivaprakash, M; Weinstein, RA | 1 |
| Abramson, MA; Chow, JW; DiNubile, MJ; Motyl, MR; Polis, A; Satishchandran, V; Teppler, H | 1 |
| Abramson, MA; Armstrong, DG; Citron, DM; Lipsky, BA; Morgenstern, DE; Tice, AD | 1 |
| Asperger, W; Chan, CY; Dela Pena, AS; DiNubile, MJ; Giezek, H; Kafka, R; Köckerling, F; Raz, R; Shivaprakash, M; Vrijens, F; Warren, B | 1 |
| Borbone, S; Cascone, C; Mezzatesta, ML; Santagati, M; Stefani, S | 1 |
| Broide, E; Raveh, D; Rudensky, B; Yinnon, AM | 1 |
| Abramson, MA; Jensen, EH; Namias, N; Solomkin, JS; Tomassini, JE | 1 |
| Abramson, MA; Armstrong, DG; Lipsky, BA; Polis, AB; Sheehan, P; Tice, AD | 1 |
| Abramson, MA; Hoey, CT; Lipsky, BA; Tice, AD; Turpin, RS; Wu, J | 1 |
| Apolônio, ACM; Coutinho, SC; Diniz, CG; Farias, LM; Geralda de Sousa-Gaia, L; Nicoli, JR; Roque de Carvalho, MA; Valéria Dos Santos, K | 1 |
| Apolônio, ACM; Carvalho, MAR; Coutinho, SC; Diniz, CG; Farias, LM; Martins, WA; Nicoli, JR; Santos, KVD | 1 |
| Chang, KT; Ledesma, KR; Quinn, JP; Tam, VH; Wang, TY | 1 |
| Carmeli, Y; Jansen, JP; Kumar, R | 1 |
| An, MM; Chen, ML; Jiang, YY; Liu, P; Shen, H; Wang, R; Zhang, JD; Zou, Z | 1 |
| Amancio Martins, W; Bahia, JL; Cara, DC; Coutinho, SC; DE Macedo Farias, L; Galuppo Diniz, C; Lopes DE Andrade, JP; Morais Apolonio, AC; Nicoli, JR; Roque DE Carvalho, MA; Valéria Dos Santos, K | 1 |
| Hawser, SP | 1 |
| Hille, DA; Namias, N; Zakrison, TL | 1 |
| Couet, W; Grégoire, N; Marliat, M; Mimoz, O; Nordmann, P; Poirel, L | 1 |
| Antunes, NT; Frase, H; Toth, M; Vakulenko, SB; Vakulenko, V | 1 |
| Chen, YH; Chen, YS; Chuang, YC; Ho, CM; Hsueh, PR; Huang, CC; Ko, WC; Lee, YL; Liu, CE; Liu, YC; Liu, YM; Lu, PL; Ni, Y; Tang, HJ; Toh, HS; Wang, JH; Xu, Y; Yu, KW | 1 |
| Bandettini, R; Buffa, P; Castagnola, E; Caviglia, I; Ciucci, A; Ginocchio, F; Guida, E; Haupt, R; Loy, A; Masa, DL; Mattioli, G; Perotti, M; Pini Prato, A | 1 |
| Cavanillas, R; Grau, S; Lozano, V; Nocea, G; Valladares, A; Xie, Y | 1 |
| Badal, RE; Cao, B; Chen, S; Chu, Y; Duan, Q; Feng, X; Gui, B; Hu, B; Hu, Z; Huang, W; Kong, H; Liao, K; Luo, Y; Ni, Y; Shao, H; Su, J; Sun, Z; Wang, Y; Wu, A; Xu, Y; Yang, Q; Yu, Y; Zhang, H; Zhang, S | 1 |
| Hung, YP; Ko, WC; Lee, JC; Li, CW; Li, MC; Lin, HJ; Liu, HC; Wu, YH | 1 |
| Gan, WJ; Mu, SM; Ran, XW; Shen, JF; Wang, J; Xian, Y; Xu, ZR; Yan, XD; Yuan, GY; Zhang, BS | 1 |
| Banerjee, R; Boyce, TG; Cunningham, SA; Hasassri, ME; Jeraldo, PR; Kaye, KS; Norgan, AP; Patel, R; Pogue, JM; Weissman, SJ | 1 |
| Dixon, N; Fowler, RC; Geyer, CN; Hanson, ND; Harrison, L; Horiyama, T; Ishii, Y; Moland, ES; Thomson, K; Yoshizumi, A | 1 |
| Carroll, K; Romagnoli, M; Simner, PJ; Wang, F; Workneh, M | 1 |
| Hackel, MA; Hoban, DJ; Karlowsky, JA; Lob, SH; Sahm, DF | 1 |
| Dizbay, M; Karaşahin, EF; Karaşahin, Ö; Özger, HS | 1 |
| Lavigne, JP; Meiller, E; Merens, A; Nicolas-Chanoine, MH; Pantel, A; Robert, J | 1 |
| Kim, JH; Kim, MJ; Sohn, JW; Yang, KS; Yoon, YK | 1 |
| Kim, HS; Kim, HY; Kim, YK; Lee, J; Lee, JA; Lee, SS; Seo, YB; Song, W; Uh, Y | 1 |
| Allerberger, F; Jesumirhewe, C; Lepuschitz, S; Ruppitsch, W; Springer, B | 1 |
| Logan, J; Mellor, TE; Mitchell, N | 1 |
3 review(s) available for penicillanic acid and ertapenem
| Article | Year |
|---|---|
Safety and tolerability of ertapenem.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; beta-Lactams; Ceftriaxone; Clinical Trials as Topic; Community-Acquired Infections; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Randomized Controlled Trials as Topic | 2004 |
Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Ertapenem; Humans; Penicillanic Acid; Piperacillin; Randomized Controlled Trials as Topic; Tazobactam; Treatment Outcome | 2009 |
Lemierre's syndrome variant of the gut.
Topics: Abdominal Pain; Anti-Bacterial Agents; Anticoagulants; beta-Lactams; Endoscopy, Gastrointestinal; Ertapenem; Fever; Fusobacterium Infections; Fusobacterium necrophorum; Heparin; Humans; Lemierre Syndrome; Male; Penicillanic Acid; Phlebitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Portal Vein; Treatment Outcome | 2017 |
19 trial(s) available for penicillanic acid and ertapenem
| Article | Year |
|---|---|
Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Ertapenem; Female; Humans; Lactams; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Penicillins; Piperacillin; Prospective Studies; Pseudomonas aeruginosa; Skin Diseases; Staphylococcus aureus; Tazobactam; Treatment Outcome | 2002 |
General microbiology and in vitro susceptibility of anaerobes isolated from complicated skin and skin-structure infections in patients enrolled in a comparative trial of ertapenem versus piperacillin-tazobactam.
Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; beta-Lactams; Double-Blind Method; Enzyme Inhibitors; Ertapenem; Humans; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Skin Diseases, Bacterial; Tazobactam | 2002 |
Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Digestive System Surgical Procedures; Double-Blind Method; Drug Therapy, Combination; Ertapenem; Female; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Hospitalization; Humans; Lactams; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Research Design; Treatment Outcome | 2003 |
Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
Topics: Abdomen; Adult; Aged; Anti-Bacterial Agents; Bacteria, Anaerobic; Bacterial Infections; beta-Lactams; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Pelvic Infection; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Skin Diseases, Bacterial; Surgical Wound Infection | 2002 |
Surgical infections with enterococcus: outcome in patients treated with ertapenem versus piperacillin-tazobactam.
Topics: Abdomen; Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Enterococcus; Ertapenem; Female; Gram-Positive Bacterial Infections; Humans; Lactams; Male; Middle Aged; Pelvic Infection; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Skin Diseases, Bacterial; Surgical Wound Infection; Treatment Outcome | 2002 |
Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
Topics: Adult; Aged; beta-Lactams; Ceftriaxone; Cephalosporins; Community-Acquired Infections; Double-Blind Method; Drug Therapy, Combination; Enterobacteriaceae Infections; Ertapenem; Escherichia coli Infections; Humans; Lactams; Middle Aged; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Tazobactam; Treatment Outcome; Urinary Tract Infections | 2003 |
[Carbapenem antibiotic ertapenem in the treatment of extrahospital intraabdominal infections].
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Double-Blind Method; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Prospective Studies; Tazobactam; Treatment Outcome | 2003 |
Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
Topics: Acute Disease; Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Ertapenem; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Lactams; Middle Aged; Pelvic Infection; Penicillanic Acid; Piperacillin; Probability; Prospective Studies; Risk Assessment; Severity of Illness Index; Tazobactam; Treatment Outcome | 2003 |
Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Ertapenem; Female; Humans; Infusions, Intravenous; Lactams; Logistic Models; Male; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Skin Diseases; Statistics, Nonparametric; Tazobactam; Treatment Outcome | 2004 |
Management of complicated appendicitis and comparison of outcome with other primary sites of intra-abdominal infection: results of a trial comparing ertapenem and piperacillin-tazobactam.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Bacterial Agents; Appendicitis; Bacterial Infections; beta-Lactams; Colonic Diseases; Demography; Double-Blind Method; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Risk Factors; Severity of Illness Index | 2004 |
Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam.
Topics: Abdomen; Adolescent; Adult; Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bacterial Infections; beta-Lactams; Double-Blind Method; Ertapenem; Female; Humans; Lactams; Male; Pelvic Infection; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Skin Diseases, Bacterial; Treatment Outcome | 2004 |
Efficacy of ertapenem against methicillin-susceptible Staphylococcus aureus in complicated skin/skin structure infections: results of a double-blind clinical trial versus piperacillin-tazobactam.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Double-Blind Method; Ertapenem; Female; Humans; Lactams; Male; Methicillin Resistance; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Skin Diseases, Bacterial; Staphylococcal Infections; Staphylococcus aureus | 2004 |
Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Carrier State; Ceftriaxone; Digestive System Surgical Procedures; Drug Resistance, Bacterial; Drug Therapy, Combination; Ertapenem; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Intestines; Lactams; Male; Metronidazole; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2005 |
Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Double-Blind Method; Drug Resistance, Bacterial; Drug Therapy, Combination; Enterobacteriaceae; Ertapenem; Female; Humans; Lactams; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Rectum; Treatment Outcome | 2005 |
Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactams; Diabetic Foot; Double-Blind Method; Drug Administration Schedule; Ertapenem; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Severity of Illness Index; Treatment Outcome | 2005 |
Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention.
Topics: Abdomen; Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anti-Bacterial Agents; Bacterial Infections; Bacteroides fragilis; Bacteroides Infections; beta-Lactams; Diarrhea; Ertapenem; Escherichia coli Infections; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Treatment Outcome | 2006 |
Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults.
Topics: Abdominal Abscess; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; APACHE; Bacterial Infections; Bacteroides; beta-Lactams; Double-Blind Method; Ertapenem; Escherichia coli; Female; Humans; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2007 |
Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibitors; beta-Lactams; China; Diabetic Foot; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Ertapenem; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Treatment Outcome; Young Adult | 2016 |
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Cephalosporins; Cross Infection; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Genotype; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Republic of Korea; Tazobactam; Urinary Tract Infections | 2017 |
29 other study(ies) available for penicillanic acid and ertapenem
| Article | Year |
|---|---|
In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Ceftriaxone; Community-Acquired Infections; Drug Resistance, Microbial; Drug Therapy, Combination; Enterobacteriaceae; Ertapenem; Haemophilus influenzae; Humans; Lactams; Microbial Sensitivity Tests; Moraxella catarrhalis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Staphylococcus aureus; Streptococcus agalactiae; Streptococcus pyogenes | 2002 |
Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Drug Resistance, Bacterial; Drug Therapy, Combination; Enzyme Inhibitors; Ertapenem; Escherichia coli; Escherichia coli Infections; Lactams; Microbial Sensitivity Tests; Penicillanic Acid; Tazobactam | 2004 |
[Investigation of the in-vitro effectiveness of ertapenem against Pseudomonas aeruginosa strains isolated from intensive care unit patients].
Topics: Anti-Bacterial Agents; beta-Lactams; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Intensive Care Units; Lactams; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2004 |
Bactericidal activity of ertapenem against major intra-abdominal pathogens.
Topics: Abdomen; Anti-Bacterial Agents; Bacterial Infections; Bacteroides fragilis; beta-Lactams; Ceftazidime; Ceftriaxone; Digestive System Diseases; Enterobacter cloacae; Enterococcus faecalis; Ertapenem; Escherichia coli; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Klebsiella; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus mirabilis; Staphylococcus aureus; Time Factors | 2006 |
Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clavulanic Acid; Drug Interactions; Ertapenem; Escherichia coli; Klebsiella pneumoniae; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Thienamycins | 2007 |
Clinical predictors of treatment failure for diabetic foot infections: data from a prospective trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Diabetic Foot; Ertapenem; Female; Humans; Leukocyte Count; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Severity of Illness Index; Treatment Failure | 2007 |
Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Diabetic Foot; Drug Administration Schedule; Drug Combinations; Ertapenem; Female; Health Care Costs; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2007 |
In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures.
Topics: Anti-Bacterial Agents; Bacteroides fragilis; beta-Lactams; Colony Count, Microbial; Ertapenem; Escherichia coli; Microbial Sensitivity Tests; Microbial Viability; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time Factors | 2007 |
Comparative activity of ertapenem and piperacillin tazobactam in a murine systemic infection model with Bacteroides fragilis and Escherichia coli.
Topics: Animals; Anti-Bacterial Agents; Ascitic Fluid; Bacteroides fragilis; Bacteroides Infections; beta-Lactams; Blood; Colony Count, Microbial; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Mice; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sepsis | 2007 |
Killing of Escherichia coli by beta-lactams at different inocula.
Topics: Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Ceftriaxone; Colony Count, Microbial; Ertapenem; Escherichia coli; Humans; Microbial Viability; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Time Factors | 2009 |
Accounting for the development of antibacterial resistance in the cost effectiveness of ertapenem versus piperacillin/tazobactam in the treatment of diabetic foot infections in the UK.
Topics: Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Cost-Benefit Analysis; Decision Trees; Diabetic Foot; Direct Service Costs; Drug Costs; Drug Resistance, Bacterial; Ertapenem; Humans; Models, Biological; Models, Econometric; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Quality-Adjusted Life Years; Treatment Outcome; United Kingdom | 2009 |
In vitro selection of ertapenem and piperacillin/tazobactam-resistant strains of Bacteroides fragilis and analysis of their virulence in gnotobiotic mice.
Topics: Animals; Anti-Bacterial Agents; Bacteroides fragilis; Bacteroides Infections; beta-Lactam Resistance; beta-Lactams; Ertapenem; Germ-Free Life; In Vitro Techniques; Mice; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Tazobactam; Virulence | 2010 |
Superior in vitro activity of ertapenem and piperacillin/tazobactam against recent clinical isolates of Proteus mirabilis from intra-abdominal infections (SMART 2009-2010).
Topics: Abdominal Abscess; Anti-Bacterial Agents; beta-Lactams; Ertapenem; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus Infections; Proteus mirabilis | 2011 |
Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillin-tazobactam.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactams; Body Mass Index; Ertapenem; Female; Humans; Intraabdominal Infections; Male; Middle Aged; Multicenter Studies as Topic; Obesity, Morbid; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Randomized Controlled Trials as Topic; Young Adult | 2012 |
Broad-spectrum β-lactam antibiotics for treating experimental peritonitis in mice due to Klebsiella pneumoniae producing the carbapenemase OXA-48.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Cefotaxime; Ceftazidime; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Ertapenem; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Lethal Dose 50; Mice; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasmids; Survival Rate | 2012 |
Class A carbapenemase FPH-1 from Francisella philomiragia.
Topics: Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Clavulanic Acid; Doripenem; Ertapenem; Escherichia coli; Francisella; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Sulbactam; Tazobactam; Thienamycins | 2012 |
Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
Topics: Amikacin; Anti-Bacterial Agents; Asia; Australasia; beta-Lactamases; beta-Lactams; Carbapenems; Ceftazidime; Drug Resistance, Bacterial; Ertapenem; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prevalence; Prospective Studies; Urinary Tract Infections | 2012 |
Susceptibility to antibiotics of aerobic bacteria isolated from community acquired secondary peritonitis in children: therapeutic guidelines might not always fit with and everyday experience.
Topics: Ampicillin; Anti-Bacterial Agents; Bacterial Infections; beta-Lactams; Child; Community-Acquired Infections; Drug Resistance, Bacterial; Drug Therapy, Combination; Ertapenem; Gentamicins; Hospitals, Pediatric; Humans; Italy; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Practice Guidelines as Topic; Sulbactam; Thienamycins | 2013 |
Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis.
Topics: Anti-Bacterial Agents; APACHE; beta-Lactams; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Cost-Benefit Analysis; Decision Trees; Double-Blind Method; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Ertapenem; Humans; Intraabdominal Infections; Length of Stay; Models, Economic; Monte Carlo Method; Multicenter Studies as Topic; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Spain | 2015 |
Antimicrobial Susceptibilities of Aerobic and Facultative Gram-Negative Bacilli from Intra-abdominal Infections in Patients from Seven Regions in China in 2012 and 2013.
Topics: Amikacin; Ampicillin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Cefoxitin; China; Ciprofloxacin; Community-Acquired Infections; Cross Infection; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Ertapenem; Gene Expression; Humans; Imipenem; Intraabdominal Infections; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Sulbactam | 2016 |
Antimicrobial susceptibility of clinical Enterobacteriaceae isolates at the emergency department in a regional hospital: A threat of extended spectrum beta-lactamase-producers among nursing home residents.
Topics: Amikacin; Anti-Bacterial Agents; beta-Lactamases; beta-Lactams; Blood; Drug Resistance, Multiple, Bacterial; Emergency Service, Hospital; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Klebsiella Infections; Klebsiella pneumoniae; Male; Meropenem; Microbial Sensitivity Tests; Nursing Homes; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus Infections; Proteus mirabilis; Retrospective Studies; Sputum; Taiwan; Thienamycins; Urine | 2016 |
An Immunocompromised Child with Bloodstream Infection Caused by Two Escherichia coli Strains, One Harboring NDM-5 and the Other Harboring OXA-48-Like Carbapenemase.
Topics: Adolescent; Amikacin; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactamases; beta-Lactams; Ciprofloxacin; Ertapenem; Escherichia coli; Female; Gentamicins; Humans; Immunocompromised Host; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Tazobactam; Thienamycins; Tobramycin | 2016 |
IMP-27, a Unique Metallo-β-Lactamase Identified in Geographically Distinct Isolates of Proteus mirabilis.
Topics: Aztreonam; beta-Lactamases; beta-Lactams; Ceftazidime; Drug Resistance, Bacterial; Ertapenem; Hydrolysis; Integrons; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Proteus Infections; Proteus mirabilis; United States | 2016 |
Bypass graft infection and bacteremia caused by Anaerostipes caccae: First report of human infection caused by a recently described gut anaerobe.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anastomosis, Surgical; Anti-Bacterial Agents; beta-Lactams; Blood Culture; Clostridiales; Ertapenem; Female; Gram-Positive Bacterial Infections; Humans; Metronidazole; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Surgical Wound Infection; Vancomycin | 2016 |
Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.
Topics: Acinetobacter baumannii; Amikacin; Anti-Infective Agents; Asia; beta-Lactamases; beta-Lactams; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacter; Ertapenem; Gram-Negative Bacteria; Hospitalization; Humans; Imipenem; Intraabdominal Infections; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Urinary Tract Infections | 2017 |
Treatment efficacy and superinfection rates in complicated urinarytract infections treated with ertapenem or piperacillin tazobactam.
Topics: Anti-Bacterial Agents; beta-Lactams; Ertapenem; Humans; Penicillanic Acid; Piperacillin; Retrospective Studies; Superinfection; Tazobactam; Treatment Outcome | 2016 |
Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratory.
Topics: Algorithms; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; beta-Lactams; Carbapenems; Cefepime; Cephalosporins; Clavulanic Acids; Drug Resistance, Bacterial; Enterobacteriaceae; Ertapenem; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Tazobactam; Thienamycins; Ticarcillin | 2017 |
Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Hospitals, University; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Republic of Korea; Retrospective Studies; Survival Analysis; Treatment Failure; Young Adult | 2017 |
Carbapenemase-Producing Enterobacteriaceae Isolates from Edo State, Nigeria.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenem-Resistant Enterobacteriaceae; Cefotaxime; Ceftazidime; Disk Diffusion Antimicrobial Tests; Enterobacteriaceae Infections; Ertapenem; Fluoroquinolones; Humans; Nigeria; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2017 |